UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 179

Sortiert nach

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Annals of oncology, 2019-12, Vol.30 (12), p.1950-1958

2019

Volltextzugriff (PDF)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma

British journal of cancer, 2013-08, Vol.109 (3), p.739-746

2013

Volltextzugriff (PDF)

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

British journal of cancer, 2007-07, Vol.97 (2), p.170-176

2007

Volltextzugriff (PDF)

Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas

Japanese journal of clinical oncology, 2010-04, Vol.40 (4), p.313-318

2010

Volltextzugriff (PDF)

ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer

British journal of cancer, 2015-02, Vol.112 (4), p.704-713

2015

Volltextzugriff (PDF)

Phase II study of S-1 in patients with advanced biliary tract cancer

British journal of cancer, 2004-11, Vol.91 (10), p.1769-1774

2004

Volltextzugriff (PDF)

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

Neuroendocrinology, 2012-01, Vol.96 (4), p.324-332

2012

Volltextzugriff (PDF)

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer

Annals of oncology, 2018-10, Vol.29, p.viii216-viii217

2018

Volltextzugriff (PDF)

A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma

Annals of oncology, 2018-10, Vol.29, p.viii234-viii235

2018

Volltextzugriff (PDF)

P-103Prognostic factors for survival in patients with advanced intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line treatment

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii30-ii30

2016

Volltextzugriff (PDF)

P-120Gemcitabine + nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii35-ii35

2016

Volltextzugriff (PDF)

Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

Annals of oncology, 2018-10, Vol.29, p.viii248-viii249

2018

Volltextzugriff (PDF)

The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer

Annals of oncology, 2018-10, Vol.29, p.viii208-viii209

2018

Volltextzugriff (PDF)

Homozygous CDA3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

British journal of cancer, 2009-03, Vol.100 (6), p.870-873

2009

Volltextzugriff (PDF)

P-122Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for Unresectable pancreatic ductal adenocarcinoma

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii36-ii36

2016

Volltextzugriff (PDF)

P-119Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii35-ii35

2016

Volltextzugriff (PDF)

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced biliary tract cancer

Annals of oncology, 2017-09, Vol.28, p.v244-v244

2017

Volltextzugriff (PDF)

First-in-man phase 1 study of TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S120-S120

2016

Volltextzugriff (PDF)

The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology

ESMO open, 2024-04, Vol.9 (4), p.102981-102981, Article 102981

2024

Volltextzugriff (PDF)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

British journal of cancer, 2004-08, Vol.91 (4), p.673-677

2004

Volltextzugriff (PDF)

2382 A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers

European journal of cancer (1990), 2015-09, Vol.51, p.S464-S464

2015

Volltextzugriff (PDF)

2313 Multicenter retrospective analysis of pancreatic acinar cell carcinoma: Overall survival and potential benefit of platinum- or irinotecan-containing chemotherapy

European journal of cancer (1990), 2015-09, Vol.51, p.S437-S437

2015

Volltextzugriff (PDF)

6574 POSTER Thirty-four Cases of Advanced Ampullary Carcinoma Receiving Non-surgical Treatment – Experience at a Single Center

European journal of cancer (1990), 2011, Vol.47, p.S463-S463

2011

Volltextzugriff (PDF)

A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

British journal of cancer, 2007-06, Vol.96 (11), p.1650-1655

2007

Volltextzugriff (PDF)

341P Clinical experience with S-1 or FOLFOX as third-line treatment in patients with metastatic pancreatic cancer who received first-line gemcitabine + nab-paclitaxel and second-line nanoliposomal-irinotecan + 5-FU/leucovorin

Annals of oncology, 2024-06, Vol.35, p.S142-S142

2024

Volltextzugriff (PDF)

1 – 25 von 179

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(170)

Publikationsform

Sprache

Englisch
(170)
Japanisch
(29)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(50)
Humans
(46)
Male
(36)
Female
(35)
Middle Aged
(33)
Aged
(32)
Oncology
(32)
Adult
(22)
Treatment Outcome
(20)
Pancreatic Neoplasms - Drug Therapy
(18)
Chemotherapy
(17)
Biological And Medical Sciences
(16)
Medical Sciences
(15)
Deoxycytidine - Analogs & Derivatives
(14)
Pancreatic Cancer
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Hematology, Oncology And Palliative Medicine
(12)
Tumors
(12)
Gemcitabine
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas

ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer

Phase II study of S-1 in patients with advanced biliary tract cancer

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer

A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma

P-103Prognostic factors for survival in patients with advanced intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line treatment

P-120Gemcitabine + nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study

Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer

Homozygous CDA3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

P-122Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for Unresectable pancreatic ductal adenocarcinoma

P-119Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced biliary tract cancer

First-in-man phase 1 study of TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors

The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

2382 A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers

2313 Multicenter retrospective analysis of pancreatic acinar cell carcinoma: Overall survival and potential benefit of platinum- or irinotecan-containing chemotherapy

6574 POSTER Thirty-four Cases of Advanced Ampullary Carcinoma Receiving Non-surgical Treatment – Experience at a Single Center

A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

341P Clinical experience with S-1 or FOLFOX as third-line treatment in patients with metastatic pancreatic cancer who received first-line gemcitabine + nab-paclitaxel and second-line nanoliposomal-irinotecan + 5-FU/leucovorin

Suchergebnisse filtern